-
Hi Guest, want to participate in the discussions, keep track of read/unread posts access private forums and more? Create your free account and increase the benefits of your eGriz.com experience today!
Spring fb proposal
- Thread starter behappp
- Start date
The FCS situation can be simpler, as I've posted previously on other threads:
An FCS spring season doesn't have to be as bleak as many hyperbolize. Here's a scenario, first game Mar 27, 8 game conf. only season would not require a bye week. Final game May 15. 12 team playoff, a bye week for the seeded 4, play-in games May 22, quarterfinals May 29; semis June 5; NC game June 12. 90% of teams done by May 15; the wise coaches would use their depth. That's why there are 80-90 roster spots. More kids get to play.
Hard to figure the negativity regarding something so entirely new. Let's have an open mind; it could be great. For those criticizing the MT weather in March, how are November and December?
An FCS spring season doesn't have to be as bleak as many hyperbolize. Here's a scenario, first game Mar 27, 8 game conf. only season would not require a bye week. Final game May 15. 12 team playoff, a bye week for the seeded 4, play-in games May 22, quarterfinals May 29; semis June 5; NC game June 12. 90% of teams done by May 15; the wise coaches would use their depth. That's why there are 80-90 roster spots. More kids get to play.
Hard to figure the negativity regarding something so entirely new. Let's have an open mind; it could be great. For those criticizing the MT weather in March, how are November and December?
Haslam has provided several very acceptable options for season ticket holders for the fall; I'm sure there will be the same for a shortened spring season. They have absorbed a huge financial hit and need our support more than ever, but they are not going to screw anyone.reinell30 said:
OrgonGriz
Well-known member
So listened to Chip Kelly yesterday and Herm Edwards on DP show. They both hope for spring football but who knows if it happens!
My honest concern, we will be filling into the “flu” season and although not COVID just because of the number of people getting the flu think it’s COVID and it shows a false increase and increase in worry that in turn hampers spring football.
Dan P also asks why doctors in the power 5 are not all meeting to discuss how data looks. Why would SEC, ACC and Big12 allow play and Big 10 and PAC 12 don’t!
It sure would have been nice for the BSC to let fall sports play and for football at least play conf sched.
My honest concern, we will be filling into the “flu” season and although not COVID just because of the number of people getting the flu think it’s COVID and it shows a false increase and increase in worry that in turn hampers spring football.
Dan P also asks why doctors in the power 5 are not all meeting to discuss how data looks. Why would SEC, ACC and Big12 allow play and Big 10 and PAC 12 don’t!
It sure would have been nice for the BSC to let fall sports play and for football at least play conf sched.
Spanky2 said:
"Fauci has said he was hopeful that a coronavirus vaccine could be developed by early 2021, but has previously said it’s unlikely that a vaccine will deliver 100% immunity; he said the best realistic outcome, based on other vaccines, would be 70% to 75% effective. The measles vaccine, he said, is among the most effective by providing 97% immunity.
Reviews of past studies have found that, on average, the flu vaccine is about 50% to 60% effective for healthy adults who are between 18 and 64 years old, according to a review of studies by the Mayo Clinic. “The vaccine may sometimes be less effective,” it said. “Even when the vaccine doesn’t completely prevent the flu, it may lessen the severity of your illness.”
Stephen Hahn, commissioner of the Food and Drug Administration, said last month that the agency would green light a coronavirus vaccine as long as it’s 50% effective."
[Some articles I've seen are predicting lower than what Fauci thought would be a "best realistic outcome". Maybe we'll have to have multiple vaccines, and hope that the 50% or 70% doesn't overlap completely with the other vaccines. Only half-joking.]
https://www.marketwatch.com/story/fauci-says-public-should-temper-expectations-on-covid-19-vaccine-as-us-infections-near-5-million-2020-08-09
"The Treatment That Could Crush Covid
Early trials show signaling cells eliminate the virus, calm the immune response and repair tissue damage.
"But one of the most promising therapies for Covid-19 patients uses “medicinal signaling cells,” or MSCs, which are found on blood vessels throughout the body.
In preliminary studies, these cells cut the death rate significantly, particularly in the sickest patients. With a powerful 1-2-3 punch, these cells eliminate the virus, calm the immune overreaction known as a cytokine storm, and repair damaged lung tissue—a combination offered by no other drug. This type of regenerative medicine could be as revolutionary as Jonas Salk’s polio vaccine.
In one pilot study in March, doctors at Mount Sinai Hospital in New York treated a dozen severely ill Covid-19 patients on ventilators with MSCs. Two infusions modulated their hyperactive immune systems, and 83% of those patients survived. With such promising results, the team at Mount Sinai and the supplier of the cells, Mesoblast Ltd., won Food and Drug Administration clearance and National Institutes of Health funding to conduct a randomized trial on 300 patients. The first patients in the trial received the treatment in early May.
A July 10 article in the Lancet reported on 13 critically ill Covid-19 patients also treated with MSCs. Eleven of the 13 patients lived—an 85% survival rate, which mirrors the results from Mount Sinai. The number of virus-fighting T-cells rose even as inflammation fell, suggesting that these cells can control the immune response as needed. In addition, chest X-rays showed that the drug repaired lung tissue, in some cases within 48 hours.
Healing tissue is essential because the cytokine battle with the Covid-19 virus is so vicious that it punches holes in the delicate lung membranes, allowing the virus to flood into the bloodstream and body cavities. These holes must be repaired, as virus leaks create some of the complications not usually associated with respiratory infections—blood clotting, heart attacks, stroke and multiple organ failure, which cause about 40% of Covid-19-related deaths. Blood-vessel density, and thereby the number of MSCs, decreases as we age, gain weight or develop diseases, which may explain why the elderly and those with chronic health conditions are faring worst.
If the cells perform as they did at Mount Sinai in March and elsewhere, the results should be available before the end of September. A positive finding could help those most at risk of the disease’s worst effects. But the medical community and wider public are largely unaware of the potential for using MSCs to treat Covid.
https://www.wsj.com/articles/the-treatment-that-could-crush-covid-11597360709?mod=hp_opin_pos_3
Early trials show signaling cells eliminate the virus, calm the immune response and repair tissue damage.
"But one of the most promising therapies for Covid-19 patients uses “medicinal signaling cells,” or MSCs, which are found on blood vessels throughout the body.
In preliminary studies, these cells cut the death rate significantly, particularly in the sickest patients. With a powerful 1-2-3 punch, these cells eliminate the virus, calm the immune overreaction known as a cytokine storm, and repair damaged lung tissue—a combination offered by no other drug. This type of regenerative medicine could be as revolutionary as Jonas Salk’s polio vaccine.
In one pilot study in March, doctors at Mount Sinai Hospital in New York treated a dozen severely ill Covid-19 patients on ventilators with MSCs. Two infusions modulated their hyperactive immune systems, and 83% of those patients survived. With such promising results, the team at Mount Sinai and the supplier of the cells, Mesoblast Ltd., won Food and Drug Administration clearance and National Institutes of Health funding to conduct a randomized trial on 300 patients. The first patients in the trial received the treatment in early May.
A July 10 article in the Lancet reported on 13 critically ill Covid-19 patients also treated with MSCs. Eleven of the 13 patients lived—an 85% survival rate, which mirrors the results from Mount Sinai. The number of virus-fighting T-cells rose even as inflammation fell, suggesting that these cells can control the immune response as needed. In addition, chest X-rays showed that the drug repaired lung tissue, in some cases within 48 hours.
Healing tissue is essential because the cytokine battle with the Covid-19 virus is so vicious that it punches holes in the delicate lung membranes, allowing the virus to flood into the bloodstream and body cavities. These holes must be repaired, as virus leaks create some of the complications not usually associated with respiratory infections—blood clotting, heart attacks, stroke and multiple organ failure, which cause about 40% of Covid-19-related deaths. Blood-vessel density, and thereby the number of MSCs, decreases as we age, gain weight or develop diseases, which may explain why the elderly and those with chronic health conditions are faring worst.
If the cells perform as they did at Mount Sinai in March and elsewhere, the results should be available before the end of September. A positive finding could help those most at risk of the disease’s worst effects. But the medical community and wider public are largely unaware of the potential for using MSCs to treat Covid.
https://www.wsj.com/articles/the-treatment-that-could-crush-covid-11597360709?mod=hp_opin_pos_3
